Neuro-Innovators has appointed Ray Jordan as lead preferred shareholder director on its Board of Directors.
“Ray is a seasoned investor who brings a rare combination of global healthcare leadership, strategic communications expertise and experience helping innovative companies navigate periods of growth and increased visibility,” said Howison Schroeder, CEO of Neuro-Innovators. “As we advance NIV-001 in the clinic and prepare Neuro-Innovators for its next stage, his counsel will be invaluable in strengthening our corporate strategy, engaging key stakeholders and positioning the company for long-term success.”
About Ray Jordan
Jordan currently serves as Managing Director of Elmstead Partners and of Putnam Insights. “Neuro-Innovators is pursuing an ambitious and deeply important goal: helping people recover function following stroke and other neurological injuries. The team has translated a compelling scientific rationale into a capital-efficient clinical program with the potential to address a significant unmet need,” Jordan said. “I am honored to join the board and support Howison and the team as they advance NIV-001, build awareness of Neuroplastic Medicine™ and develop the partnerships needed to reach more patients.”
Jordan brings global corporate affairs and communications leadership experience spanning healthcare, technology, biotechnology, and consumer industries, having held senior roles at Moderna, Amgen, and Johnson & Johnson, and previously serving as senior communications and strategic counsel at Pfizer. His work has been recognized by industry publications including PRWeek and PRovoke Media, and his corporate employers have earned distinctions such as FORTUNE’s World’s Most Admired Companies and the Dow Jones Sustainability Index.
About Neuro-Innovators
Neuro-Innovators is a first-in-class clinical-stage pharmaceutical company focused on developing compound therapies designed to support biological pathways associated with neurological recovery following stroke, brain injury, and other neurological conditions. The company’s mission is to improve functional outcomes for patients while reducing the long-term personal and societal burden of neurologic disability, advancing its lead candidate, NIV-001, and its Neuroplastic Medicine™ approach toward that goal.
